Table 1.
Demographic and clinicopathologic characteristics of all enrolled breast cancer patients
|
Parameters Cases (n) |
262 | Low SII < 602 | High SII ≥ 602 | χ 2 | P value |
|---|---|---|---|---|---|
| 156 (59.5%) | 106 (40.5%) | ||||
| Age (years) | |||||
| <48 | 138 (52.7%) | 77 (49.4%) | 61 (57.6%) | 1.697 | .193 |
| ≥48 | 124 (47.3%) | 79 (50.6%) | 45 (42.4%) | ||
| Marital status | |||||
| Married | 243 (92.7%) | 146 (93.6%) | 97 (91.5%) | 1.883 | .757 |
| Unmarried | 9 (3.4%) | 6 (3.9%) | 3 (2.8%) | ||
| Divorce | 7 (2.7%) | 3 (1.9%) | 4 (3.8%) | ||
| Widowhood | 3 (1.2%) | 1 (0.6%) | 2 (1.9%) | ||
| Occupation | |||||
| Mental worker | 165 (63.0%) | 100 (64.1%) | 65 (61.3%) | 0.807 | .668 |
| Manual worker | 35 (13.4%) | 22 (14.1%) | 13 (12.3%) | ||
| Others | 62 (23.6%) | 34 (21.8%) | 28 (26.4%) | ||
| BMI | |||||
| <24.50 | 148 (56.5%) | 84 (53.9%) | 64 (60.4%) | 1.095 | .295 |
| ≥24.50 | 114 (43.5%) | 72 (46.1%) | 42 (39.6%) | ||
| Menopause | |||||
| No | 160 (61.1%) | 86 (55.1%) | 74 (69.8%) | 5.723 | .016 |
| Yes | 102 (38.9%) | 70 (44.9%) | 32 (30.2%) | ||
| ABO blood type | |||||
| A | 84 (32.1%) | 53 (34.0%) | 31 (29.3%) | 3.463 | .483 |
| B | 78 (29.7%) | 46 (29.5%) | 32 (30.2%) | ||
| O | 73 (27.9%) | 38 (24.4%) | 35 (33.0%) | ||
| AB | 27 (20.3%) | 19 (12.1%) | 8 (7.5%) | ||
| Tumour site | |||||
| Right | 126 (48.1%) | 77 (49.4%) | 49 (46.2%) | 0.248 | .618 |
| Left | 136 (51.9%) | 79 (50.6%) | 57 (53.8%) | ||
| Primary tumour site | |||||
| Upper outer quadrant | 166 (63.4%) | 95 (60.9%) | 71 (67.0%) | 3.351 | .501 |
| Lower outer quadrant | 21 (8.0%) | 13 (8.3%) | 8 (7.6%) | ||
| Lower inner quadrant | 12 (4.6%) | 8 (5.1%) | 4 (3.7%) | ||
| Upper inner quadrant | 38 (14.5%) | 27 (17.3%) | 11 (10.4%) | ||
| Central | 25 (9.5%) | 13 (8.4%) | 12 (11.3%) | ||
| US‐Tumour size | |||||
| ≤2 cm | 95 (36.3%) | 62 (39.7%) | 33 (31.1%) | 2.043 | .360 |
| >2 and < 5cm | 138 (52.6%) | 78 (50.0%) | 60 (56.6%) | ||
| ≥5cm | 29 (11.1%) | 16 (10.3%) | 13 (12.3%) | ||
| US‐LNM | |||||
| No | 156 (59.5%) | 101 (64.7%) | 55 (51.9%) | 4.331 | .037 |
| Yes | 106 (40.5%) | 55 (35.3%) | 51 (48.1%) | ||
| US‐BIRADS classification | |||||
| 4 | 36 (13.8%) | 20 (12.8%) | 16 (15.0%) | 1.450 | .484 |
| 5 | 103 (39.3%) | 58 (37.2%) | 45 (42.5%) | ||
| 6 | 123 (46.9%) | 78 (50.0%) | 45 (42.5%) | ||
| Clinical stage | |||||
| Clinical T stage | |||||
| T1 | 47 (17.9%) | 31 (19.9%) | 16 (15.1%) | 4.788 | .310 |
| T2 | 117 (44.7%) | 75 (48.1%) | 42 (39.6%) | ||
| T3 | 66 (25.2%) | 34 (21.8%) | 32 (30.2%) | ||
| T4 | 32 (12.2%) | 16 (10.2%) | 16 (15.1%) | ||
| Clinical N stage | |||||
| N0 | 48 (18.3%) | 29 (18.6%) | 19 (17.9%) | 3.038 | .552 |
| N1 | 89 (34.0%) | 58 (37.2%) | 31 (29.3%) | ||
| N2 | 77 (29.4%) | 45 (28.9%) | 32 (30.2%) | ||
| N3 | 48 (18.3%) | 24 (15.3%) | 24 (22.6%) | ||
| Clinical TNM stage | |||||
| II | 107 (40.8%) | 69 (44.2%) | 38 (35.9%) | 1.835 | .176 |
| III | 155 (59.2%) | 87 (55.8%) | 68 (64.1%) | ||
| Type of surgery | |||||
| Mastectomy | 221 (84.4%) | 130 (83.3%) | 91 (85.9%) | 0.302 | .582 |
| Breast‐conserving surgery | 41 (15.6%) | 26 (16.7%) | 15 (14.1%) | ||
| Tumour size | |||||
| ≤2 cm | 117 (44.7%) | 68 (43.6%) | 49 (46.2%) | 1.124 | .570 |
| >2 and < 5cm | 120 (45.8%) | 75 (48.1%) | 45 (42.5%) | ||
| ≥5cm | 25 (9.5%) | 13 (8.3%) | 12 (11.3%) | ||
| Histologic type | |||||
| Ductal | 251 (95.8%) | 148 (94.9%) | 103 (97.2%) | 2.176 | .337 |
| Lobular | 4 (1.5%) | 2 (1.3%) | 2 (1.9%) | ||
| Others | 7 (2.7%) | 6 (3.8%) | 1 (0.9%) | ||
| Histologic grade | |||||
| I | 74 (28.2%) | 41 (26.3%) | 33 (31.1%) | 1.263 | .532 |
| II | 136 (51.9%) | 81 (51.9%) | 55 (51.9%) | ||
| III | 52 (19.9%) | 34 (21.8%) | 18 (17.0%) | ||
| Pathological TNM classification | |||||
| Pathological T stage | |||||
| Tis/T0 | 42 (16.0%) | 25 (16.0%) | 17 (16.0%) | 4.331 | .363 |
| T1 | 101 (38.6%) | 60 (38.5%) | 41 (38.7%) | ||
| T2 | 82 (31.3%) | 54 (34.6%) | 28 (26.4%) | ||
| T3 | 25 (9.5%) | 12 (7.7%) | 13 (12.3%) | ||
| T4 | 12 (4.6%) | 5 (3.2%) | 7 (6.6%) | ||
| Pathological N stage | |||||
| N0 | 98 (37.4%) | 58 (37.2%) | 40 (37.7%) | 3.320 | .506 |
| N1 | 51 (19.5%) | 33 (21.2%) | 18 (17.0%) | ||
| N2 | 40 (15.3%) | 27 (17.3%) | 13 (12.3%) | ||
| N3 | 73 (27.8%) | 38 (24.3%) | 35 (33.0%) | ||
| Pathological TNM stage | |||||
| Tis/T0 | 34 (13.0%) | 18 (11.5%) | 16 (15.1%) | 2.449 | .654 |
| I | 47 (17.9%) | 31 (19.9%) | 16 (15.1%) | ||
| II | 59 (22.5%) | 38 (24.4%) | 21 (19.8%) | ||
| III | 122 (46.6%) | 69 (44.2%) | 53 (50.0%) | ||
| Total lymph nodes | |||||
| <21 | 120 (45.8%) | 72 (46.2%) | 48 (45.3%) | 0.019 | .890 |
| ≥21 | 142 (54.2%) | 84 (53.8%) | 58 (54.7%) | ||
| Positive lymph nodes | |||||
| 0 | 97 (37.0%) | 57 (36.5%) | 40 (37.7%) | 0.630 | .730 |
| <6 | 71 (27.1%) | 45 (28.9%) | 26 (24.5%) | ||
| ≥6 | 94 (35.9%) | 54 (34.6%) | 40 (37.8%) | ||
| Total axillary lymph nodes | |||||
| <20 | 118 (45.0%) | 74 (47.4%) | 44 (41.5%) | 0.896 | .344 |
| ≥20 | 144 (55.0%) | 82 (52.6%) | 62 (58.5%) | ||
| Positive axillary lymph nodes | |||||
| 0 | 99 (37.8%) | 59 (37.8%) | 40 (37.7%) | 0.676 | .713 |
| <5 | 63 (24.1%) | 40 (25.6%) | 23 (21.7%) | ||
| ≥5 | 100 (38.1%) | 57 (36.6%) | 43 (40.6%) | ||
| Post‐operative complications | |||||
| No | 253 (96.6%) | 151 (96.8%) | 102 (96.2%) | 0.061 | .804 |
| Yes | 9 (3.4%) | 5 (3.2%) | 4 (3.8%) | ||
| Post‐operative radiotherapy | |||||
| No | 61 (23.3%) | 38 (24.4%) | 23 (21.7%) | 0.250 | .617 |
| Yes | 201 (76.7%) | 118 (75.6%) | 83 (78.3%) | ||
| Post‐operative endocrine therapy | |||||
| No | 130 (49.6%) | 75 (48.1%) | 55 (51.9%) | 0.366 | .545 |
| Yes | 132 (50.4%) | 81 (51.9%) | 51 (48.1%) | ||
| Post‐operative targeted therapy | |||||
| No | 189 (72.1%) | 119 (76.3%) | 70 (66.0%) | 3.295 | .069 |
| Yes | 73 (27.9%) | 37 (23.7%) | 36 (34.0%) | ||